Obulytix featured in Euractiv’s article ‘Belgian biotech AMR breakthrough as WHO warns antibiotic pipeline is failing’

We’re proud to share that our CEO, Kristof Van Emelen, was recently interviewed by Euractiv regarding the urgent global need for next‑generation antibacterial innovation.

In the interview, Kristof discusses how Obulytix is advancing a novel therapeutic approach aimed at multidrug‑resistant Gram‑negative pathogens—an area the WHO has identified as a top priority for public health.

You can read the full interview here:👉 Belgian biotech AMR breakthrough as WHO warns antibiotic pipeline is failing

Read the full WHO update here: 👉WHO releases new target product profiles for urgently needed antibiotics